Comments for POZN - Stockpickr! Your Source for Stock Ideas

Comments for POZN

Added By	Comments	Type	Date Added
John E Houx	long time holding has caused nothing but frustration.	Love	June 28, 2009
frankreich	No business plan here... combine generic drugs and try to resell them at a premium. Insurance companies and the VA will simply not pay for it.	Hate	May 12, 2008
dianasawyermail@yahoo.com	small cap, large growth	Love	September 11, 2007
jblack50	drug stock that took big hit...destined to go back up upon approval from FDA	Love	August 28, 2007
Lucklesshero	Gamble. Looking to double up on price with approval of migraine drug.	Love	August 22, 2007
a bullish1	Counting on slow rise back to low teens	Love	August 10, 2007
Barrons	From Barron's 7-16-07: "Migraines, according to the National Library of Medicine, can be triggered by bright lights, loud noises, weather changes, smoke, perfumes, alcohol, caffeine, red wine, aged cheese, smoked fish, bacon, chocolates, nuts, avocado, bananas, onions ...you get the idea. Over the past year, 18% of U.S. women and 6% of men have suffered at least one attack. So it's easy to see why shares of a little-known drug-development company, Pozen (POZN), have run up 16% since June. Pozen has developed with GlaxoSmithKline (GSK) a tablet for treating migraines, and a regulatory decision regarding the remedy, known as Trexima, is expected Aug. 1. Option prices suggest that the market sees a 60% chance Trexima will be approved by the Food and Drug Administration, but Citigroup analyst Lucy Lu is more optimistic. She pegs the odds of an FDA nod at 80%, given Trexima's superior efficacy results in clinical trials and a safety profile comparable to Imitrex, currently the go-to drug with 55% of the U.S. market. Imitrex already is a winner for GlaxoSmithKline. Lu believes a yes could drive Pozen shares, trading at 18.50 recently, to between 23 and 25 and towards her 12-month target of 28. "We believe Trexima will be the new gold standard treatment of migraine headaches," she notes."	Love	July 14, 2007
wookiestock	immetrex approval	Love	June 12, 2007
hsiemon	Too good to enumerate	Love	May 09, 2007
Raven	Blockbuster (anticipated yearly sales of more than 1 Billion) Drug Candidates: 1. Trexima for migraines...August FDA decision. The analysts are expecting approval. Glaxo-Smith-Klein is the developmental/commercialization partner. PN 400 Arthritis medicine...Phase 3 trials to start this year. Astra Zeneca (375 million contract) is the developmental/commercialization partner. PA 325 Safer (in terms of gastrointestinal damage) Aspirin. Stellar results from the first study were released on March 6th.	Love	April 28, 2007
charles jerrier	eventually this thing will clear fda	Love	January 20, 2007